EyeBiotech is a clinical-stage ophthalmology biotech focused on developing a new generation of ocular therapies, including its lead program Restoret, a tri-specific intravitreally delivered antibody that agonizes the Wnt pathway. The company is advancing Restoret through AMARONE, a Phase 1b/2a trial, and has completed enrollment into the multiple ascending dose (MAD) portion. EyeBiotech says Restoret is designed to resolve residual retinal fluid and improve visual acuity in patients with diabetic macular edema (DME), neovascular age-related macular degeneration (NVAMD), and other retinal diseases of permeability. The company intends to use the recent proceeds to accelerate its clinical development program and further build out its retina pipeline. EyeBiotech was founded in August 2021 and operates in the United States and the United Kingdom, and its team has experience in ophthalmology drug development. The firm expanded its Series A financing to strengthen its clinical programs and pipeline progression. EyeBio is a privately held ophthalmology biotech focused on developing a new generation of ocular therapies targeting underserved patient needs. Founded in August 2021 by David Guyer, M.D., and Anthony P. Adamis, M.D., the company is assembling a diversified pipeline that combines scientifically compelling targets with innovative translational approaches. EyeBio has operations in the United States and the United Kingdom and has established a footprint in the U.K. to support clinical trial development. The company says it will use Series A proceeds to build and advance its product portfolio and is open to in‑licensing and acquisitions. EyeBio’s leadership team and board are composed of experienced ophthalmology executives and investors with prior track records in retinal drug development. The company positions itself to move quickly on development to address unmet needs in ophthalmology.

Total raised

$130M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2023